Ascendis Encocrinology Div A/S Patent-Cliff Exposure & CMS Drug Spending Portfolio

Ascendis Encocrinology Div A/S (US): 1 reconciled FDA prescription therapies, $118.4M 2024 CMS Part D & Medicaid spend, and 9 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$118.4M
2024 Medicare Part D Spend$159K
2024 Medicaid Spend$118.2M
California HCAI SB 17 Filings9 WAC filings (max 16.3% 2-yr change)